页 1 从 20 结果
DESCRIPTION
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention is generally related to the therapeutic use of .DELTA..sup.9 Tetrahydrocannabinol (.DELTA..sup.9 THC). In particular, the invention provides a metered dose inhaler (MDI) for the aerosol administration of .DELTA..sup.9
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention is generally related to the therapeutic use of .DELTA..sup.9 Tetrahydrocannabinol (.DELTA..sup.9 THC). In particular, the invention provides a metered dose inhaler (MDI) for the aerosol administration of .DELTA..sup.9 THC to
BACKGROUND
Cannabinoid receptors, CB1 and CB2, are part of the endocannabinoid system (ECS), which consists of cannabinoid receptors, endogenous endocannabinoids anandamide (AEA) and 2-arachindonoylglycerol (2-AG) and the hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol
BACKGROUND OF THE INVENTION
Mammalian Endogenous Cannabinoid System
The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types
BACKGROUND OF THE INVENTION
Mammalian Endogenous Cannabinoid System
The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types
BACKGROUND OF THE INVENTION
Mammalian Endogenous Cannabinoid System
The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types
FIELD OF THE INVENTION
The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase and are useful for the treatment of conditions affected by inhibiting fatty acid amide
This invention relates to novel amide derivatives of certain 2,6-methano-2H-quinolizines-type compounds, to the intermediates and processes for their preparation, to their ability to antagonize the effects of serotonin at the 5HT.sub.3 receptors, and to their end-use application in the treatment of
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
BACKGROUND
.DELTA..sup.9 -Tetrahydrocannabinol, the pyschoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to
BACKGROUND
.DELTA..sup.9 -Tetrahydrocannabinol, the pyschoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to
BACKGROUND
.DELTA..sup.9 -Tetrahydrocannabinol, the psychoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to
BACKGROUND
.DELTA..sup.9 -Tetrahydrocannabinol, the pyschoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to
FIELD OF THE INVENTION
The present invention relates generally to cannabinoid analogs and is more particularly concerned with new and improved retro-anandamide cannabinoid analogs exhibiting high binding affinities for cannabinoid receptors, pharmaceutical preparations employing these analogs and